Pfizer Independent Medical Education Grant - New Mechanisms and Emerging Treatment Options in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Organization
Pfizer
Type
Industry
Application Due Date
10-21-2026
Brief Description

This competitive grant program seeks to support independent medical education addressing the new mechanisms in mCRPC including EZH2 inhibition and its possible role in prostate cancer and the continued unmet need for novel therapies in mCRPC.